Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4261 to 4275 of 8906 results

  1. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  2. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  3. Positive workplaces for social workers

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers {"@context":"http://schema

  4. Maintaining contact with service users

    Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Mental health services {"@context":"http://schema.org"

  5. Hypertension: ECG for target organ damage (IND123)

    This indicator covers the percentage of patients with a new diagnosis of hypertension in the preceding 1 April to 31 March who have a record of a 12-lead ECG performed in the 3 months before or after the date of entry to the hypertension register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM77

  6. Lung cancer: Treatment pathways

    Download (PDF) Treatment pathways We have produced treatment pathways bringing together NICE

  7. A new model for evaluating and purchasing antimicrobials in the UK

    Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.

  8. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  9. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

  10. TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)

    NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .

  11. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

  12. Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

    NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .

  13. Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)

    NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .

  14. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

  15. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional